Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Non-randomized, Phase I Dose Escalation Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY1163877 in Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors

NCT01976741 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT01976741
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01976741 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Non-randomized, Phase I Dose Escalation Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY1163877 in Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Completed
Start date
December 30, 2013
Completion date
January 9, 2020
Enrollment
168 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms